• Dr. Steven Kirkham

Adverum Biotechnologies is attempting approval of a single-dose gene therapy...

This gene therapy can express the drug aflibercept, used for treating macular degeneration, for up to 16 months, researchers reported in Molecular Therapy. This novel treatment—fast-tracked by the FDA earlier this year—is now undergoing a phase 1 trial in humans. Longer-lasting treatment for macular degeneration would solve the burdensome requirement in such patients of having repeated, sometimes monthly, injections of shorter-acting medications for long periods of time. Adverum Biotechnologies, Molecular Therapy